Cargando…

Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer

BACKGROUND: Recent advances in T cell-related immunotherapy have brought remarkable progress in the treatment of non-small cell lung cancer (NSCLC). However, whether and how genetic variations of T cell cancer immune response genes can influence clinical outcomes of NSCLC patients remain obscure. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qinchuan, Gu, Jianchun, Wang, Linbo, Chang, David W, Ye, Yuanqing, Huang, Maosheng, Roth, Jack A, Wu, Xifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412613/ https://www.ncbi.nlm.nih.gov/pubmed/32764075 http://dx.doi.org/10.1136/jitc-2019-000336

Ejemplares similares

Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells
por: Wang, Sheng, et al.
Publicado: (2023)

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Intratumoral TIGIT(+) CD8(+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer
por: Liu, Zhaopei, et al.
Publicado: (2020)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
por: Zhou, Liye, et al.
Publicado: (2022)

Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling
por: Jiao, Shiping, et al.
Publicado: (2022)

Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade
por: Luo, Yan, et al.
Publicado: (2023)

ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response
por: de Sousa, Luana Guimaraes, et al.
Publicado: (2022)

Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages
por: Potluri, Hemanth K, et al.
Publicado: (2020)

Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments
por: Nguyen, Sylvain, et al.
Publicado: (2022)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio
por: Crosby, Erika J, et al.
Publicado: (2020)

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
por: Abdul Sater, Houssein, et al.
Publicado: (2020)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
por: Chen, Minjiang, et al.
Publicado: (2023)

Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer
por: Henick, Brian S, et al.
Publicado: (2022)

Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells
por: Liu, Yue, et al.
Publicado: (2023)

Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma
por: Restle, David, et al.
Publicado: (2023)

Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer
por: Arai, Hiroyuki, et al.
Publicado: (2020)

Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway
por: Shen, Ye, et al.
Publicado: (2022)

Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy
por: Ferdinandus, Justin, et al.
Publicado: (2021)

Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling
por: Aguirre-Ducler, Adam, et al.
Publicado: (2022)

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
por: Deng, Jia-Yi, et al.
Publicado: (2023)

Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016
por: Sussman, Tamara A, et al.
Publicado: (2022)

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
por: Zhou, Quan, et al.
Publicado: (2020)

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer
por: Busenhart, Philipp, et al.
Publicado: (2022)

Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer
por: Khorana, Alok A, et al.
Publicado: (2023)

Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma
por: Chakiryan, Nicholas H, et al.
Publicado: (2023)

CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype
por: Li, Han, et al.
Publicado: (2022)

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
por: Zou, Fangwen, et al.
Publicado: (2021)

Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer
por: McCann, Katy, et al.
Publicado: (2022)

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
por: Qiao, Meng, et al.
Publicado: (2022)

Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer
por: Hecht, Markus, et al.
Publicado: (2022)

Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events
por: Gente, Karolina, et al.
Publicado: (2023)

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
por: Jing, Ying, et al.
Publicado: (2022)

Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration
por: Sultan, Hussein, et al.
Publicado: (2020)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
por: Chen, Xin, et al.
Publicado: (2020)

Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
por: Pan, Yuanwang, et al.
Publicado: (2022)

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
por: Bae, Seongman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_80tnbhs25of1gan0cv02ticu5r